Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly docetaxel plus androgen-deprivation therapy in previously untreated metastatic prostate adenocarcinoma
KCT0003546Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel in prostate adenocarcinoma, metastatic castration-resistant prostate cancer (mCRPC), sponsored by Sanofi. Started Aug 2018; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate adenocarcinomametastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on KCT0003546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003546.